<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01397019</url>
  </required_header>
  <id_info>
    <org_study_id>DPSG 2010-01</org_study_id>
    <nct_id>NCT01397019</nct_id>
  </id_info>
  <brief_title>Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours</brief_title>
  <official_title>Chemotherapy for Patients With Locally Advanced Pancreatic Cancer With Additional Chemo-radiotherapy for Patients With Borderline Resectable Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Pfeiffer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treating patients with initial local non-resectable pancreatic cancer with a combination of&#xD;
      oxaliplatin, irinotecan &amp; 5-FU(FOLFIRINOX), consolidated with chemoradiotherapy in&#xD;
      potentially resectable patients, will result in a high rate of tumor shrinkage allowing&#xD;
      subsequent resection in patients with initial borderline resectable tumors and improved&#xD;
      overall survival for all patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer (PC) is the third most common gastrointestinal malignancy and one of the&#xD;
      top ten leading causes of cancer deaths in the Western world. Patients with PC can be divided&#xD;
      into three subgroups; resectable (rPC), locally advanced (LAPC) and metastatic (mPC). For&#xD;
      patients with rPC surgery offers the best chance for long term survival. However it is&#xD;
      estimated that only 20% of patients have rPC at the time of diagnosis. For patients with&#xD;
      LACP, invasion of local large vessels is most often the cause for non-resectability. The&#xD;
      median survival of these patients is between 6 to 12 months and long term survival in is&#xD;
      extremely rare. The optimal treatment of LAPC is controversial. Treatment strategies vary&#xD;
      between attempts to &quot;downstage&quot; the tumour to rPC, or treat the patients in a palliative&#xD;
      setting only. Phase II studies and retrospective series have evaluated various treatments&#xD;
      regimens and strategies including chemotherapy and radiotherapy (RT) alone or in combination&#xD;
      - chemoradiotherapy (CRT). Results from these trials give no clear answer regarding the best&#xD;
      treatment strategy. However, data from several studies shows that treatment of LAPC may&#xD;
      result in shrinkage of the tumour, and thus potentially lead to a resection; also data&#xD;
      suggests that CRT after chemotherapy improves treatment efficacy. Recent data from patients&#xD;
      with mPC has show a combination of oxaliplatin, irinotecan and 5-FU (FOLFIRINOX) increases&#xD;
      response rates from 10% to 30% and median survival to 11.1 months. The promising efficacy&#xD;
      makes it natural to attempt this treatment in patients with LAPC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2011</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2 year survival rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFIRINOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, irinotecan, 5-FU &amp; leucovorin</intervention_name>
    <description>FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors</description>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (major)&#xD;
&#xD;
          -  non-metastatic pancreatic cancer&#xD;
&#xD;
          -  Performance status 0-1&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 UNL&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria: (major)&#xD;
&#xD;
          -  no prior abdominal radiotherapy&#xD;
&#xD;
          -  no prior chemotherapy for pancratic cancer&#xD;
&#xD;
          -  no severe comorbidity&#xD;
&#xD;
          -  patients must be able to undergo potential abdominal surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Pfeiffer, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 18, 2011</study_first_submitted>
  <study_first_submitted_qc>July 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2011</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Per Pfeiffer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

